#1 Clinical Trials Search in Europe

BENZYLPENICILLIN POTASSIUM

Benzylpenicillin potassium, also known as penicillin G potassium, is an important antibiotic used to treat various bacterial infections. This article explores how this medication is being studied in clinical trials for conditions ranging from neurosyphilis in HIV-positive individuals to severe pneumonia, complicated urinary tract infections, and Staphylococcus aureus bloodstream infections. These trials aim to determine optimal dosing regimens, effectiveness compared to other antibiotics, and innovative delivery methods to improve patient outcomes and reduce hospital stays.

Table of Contents

What is Benzylpenicillin Potassium?

Benzylpenicillin potassium, also known as penicillin G potassium or simply penicillin G, is an antibiotic medication belonging to the penicillin class. It is one of the oldest and most widely used antibiotics in medicine today. Benzylpenicillin was one of the first antibiotics discovered and has been used since the mid-1940s to treat various bacterial infections [1].

This antibiotic is available under several names, including:

  • Benzylpenicillin
  • Penicillin G
  • Penicillin G potassium
  • Medipen
  • Cristapen

How Benzylpenicillin Works

Benzylpenicillin belongs to the beta-lactam family of antibiotics. It works by interfering with the bacteria’s ability to form cell walls, which are essential for bacterial survival. Specifically, benzylpenicillin binds to proteins called penicillin-binding proteins (PBPs) that are involved in the final stage of building the bacterial cell wall. This causes the cell wall to weaken and eventually rupture, killing the bacteria [2].

This mechanism makes benzylpenicillin a bactericidal antibiotic, meaning it directly kills bacteria rather than just preventing them from multiplying (as bacteriostatic antibiotics do). Benzylpenicillin is most effective against gram-positive bacteria, though it also works against some gram-negative bacteria [3].

Medical Uses

Benzylpenicillin is used to treat a variety of infections caused by susceptible bacteria. Based on clinical trial data, some of the main uses include:

  • Neurosyphilis (infection of the brain or spinal cord caused by the bacterium Treponema pallidum), particularly in patients with HIV [1]
  • Bloodstream infections caused by penicillin-susceptible Staphylococcus aureus (PSSA) [2]
  • Pneumonia (infection of the lungs) [3]
  • Complicated urinary tract infections, particularly in children [4]

Benzylpenicillin for Neurosyphilis in HIV Patients

Neurosyphilis is a serious condition that occurs when the bacterium that causes syphilis infects the central nervous system. For patients who are also HIV-positive, treating neurosyphilis can be particularly challenging. Studies have shown that benzylpenicillin is effective as a treatment option for these patients [1].

In a clinical trial comparing benzylpenicillin with ceftriaxone for treating neurosyphilis in HIV-positive patients, researchers found that both treatments were effective. Traditionally, treating neurosyphilis required hospitalization for intravenous benzylpenicillin administration, but the study explored whether ceftriaxone could provide an effective outpatient alternative [1].

For neurosyphilis treatment, benzylpenicillin is typically administered intravenously for 10 days, with careful monitoring of the patient’s response through procedures such as lumbar punctures to check spinal fluid [1].

Treating Staphylococcus Aureus Infections

Staphylococcus aureus is a common bacterium that can cause serious infections, particularly when it enters the bloodstream (a condition known as bacteremia). While many strains of S. aureus have developed resistance to penicillin over the years, some strains remain susceptible. These are known as penicillin-susceptible Staphylococcus aureus (PSSA) [2].

Research suggests there may be theoretical advantages to using benzylpenicillin over other antibiotics like flucloxacillin or cloxacillin for treating PSSA infections. These advantages include:

  • A lower MIC (minimum inhibitory concentration) distribution, meaning benzylpenicillin can be effective at lower concentrations
  • Higher levels of free non-protein-bound drug concentrations in the blood
  • Potentially favorable side effect profile [2]

Clinical trials are ongoing to determine whether benzylpenicillin is superior to other treatments for PSSA bloodstream infections. For example, the PANFLUTE study compared benzylpenicillin to flucloxacillin for treatment of PSSA bacteremia, while another trial is comparing benzylpenicillin to cloxacillin for the same condition [2][5].

Treating Pneumonia

Pneumonia is a serious infection of the lungs that can be life-threatening, especially in young children and critically ill patients. Benzylpenicillin is one of the antibiotics used to treat pneumonia, particularly in hospital settings [3].

The World Health Organization (WHO) recommends benzylpenicillin plus gentamicin as the standard treatment for severe pneumonia in children. This combination provides coverage against a wide range of bacteria that might cause the infection [6].

For critically ill patients with pneumonia in intensive care units (ICUs), research is being conducted to determine the optimal dosing of benzylpenicillin to ensure effective concentrations in both the blood and the infection site in the lungs (the epithelial lining fluid) [7].

Treating Urinary Tract Infections

Complicated urinary tract infections (UTIs) in children sometimes require treatment with intravenous antibiotics. Benzylpenicillin may be used as part of the treatment regimen, particularly when there is concern about infection with Enterococcus bacteria [4].

In a clinical trial investigating treatment of complicated UTIs in children, benzylpenicillin was used in combination with gentamicin. The study compared a single dose of these intravenous antibiotics followed by oral antibiotics versus three days of intravenous antibiotics [4].

How Benzylpenicillin is Administered

Benzylpenicillin is typically administered in the following ways:

  • Intravenous (IV) injection or infusion: The medication is delivered directly into a vein. This is the most common method for serious infections.
  • Intramuscular (IM) injection: The medication is injected into a muscle, typically in the buttocks or thigh.
  • Continuous infusion: For some conditions, benzylpenicillin may be administered as a continuous infusion over a period of time rather than intermittent doses [3].

There is also a long-acting form called benzathine benzylpenicillin that is administered as an intramuscular injection and provides prolonged release of the antibiotic [8].

Dosing Information

The dosage of benzylpenicillin varies depending on the type and severity of the infection, the patient’s age, weight, and kidney function. Here are some common dosing regimens based on clinical trial data:

For Adults:

  • Standard dose: 1.2g to 1.8g every 4-6 hours intravenously [2]
  • For severe infections or critical illness: 2.4g every 4 hours intravenously [2]
  • For continuous infusion (e.g., home IV therapy): 10.8g to 14.4g per 24 hours [2]

For Children:

  • Age 1 month to 18 years: 30 mg/kg (maximum 1.2g) every 6 hours intravenously or intramuscularly [4]
  • For severe infections: Up to 60 mg/kg (maximum 2.4g) every 4-6 hours [4]

Dosing in Renal Impairment:

  • Creatinine clearance <50 ml/min and >10 ml/min: 25% reduction of dose [2]
  • Creatinine clearance <10 ml/min or on hemodialysis: 50% reduction of dose [2]
  • On continuous renal replacement therapy: 1.8g every 4 hours [2]

Advanced Delivery Methods

Researchers are exploring innovative ways to optimize the delivery of benzylpenicillin to improve treatment outcomes. One such approach is the use of closed-loop control systems with biosensor technology [3].

This technology involves:

  • A microneedle biosensor placed in the patient’s arm to monitor antibiotic levels in real-time
  • Automated adjustment of the antibiotic infusion rate based on the measured levels
  • The goal of maintaining optimal antibiotic concentrations throughout treatment [3]

This approach could be particularly beneficial for ensuring that benzylpenicillin concentrations remain above the minimum inhibitory concentration (MIC) of the target bacteria for the entire dosing interval, which is important for optimal antibacterial effect [3].

Side Effects and Precautions

Like all medications, benzylpenicillin can cause side effects. Common side effects include:

  • Allergic reactions: Ranging from mild rashes to severe anaphylactic reactions. Allergy to penicillin is one of the most common drug allergies.
  • Gastrointestinal effects: Nausea, vomiting, and diarrhea.
  • Injection site reactions: Pain, inflammation, or phlebitis (inflammation of a vein) at the injection site.
  • Liver effects: Rarely, benzylpenicillin can cause elevated liver enzymes.
  • Kidney effects: Changes in kidney function may occur, particularly with high doses or in patients with pre-existing kidney problems.
  • Hematologic effects: Rarely, benzylpenicillin can affect blood cell counts [2].

Before receiving benzylpenicillin, you should inform your healthcare provider if you have:

  • A history of allergic reactions to penicillin or other antibiotics
  • Kidney problems
  • Liver disease
  • Any other medical conditions or if you are pregnant or breastfeeding [3]

Current Research

Several ongoing clinical trials are investigating the use of benzylpenicillin for various conditions:

  • Comparing benzylpenicillin to cloxacillin for treatment of penicillin-susceptible Staphylococcus aureus bacteremia [5]
  • Evaluating optimal dosing strategies for benzylpenicillin in critically ill patients with pneumonia [7]
  • Investigating the use of a single dose of intravenous antibiotics (including benzylpenicillin when appropriate) followed by oral antibiotics for complicated urinary tract infections in children [4]
  • Testing closed-loop control systems with biosensor technology for automated delivery of benzylpenicillin [3]

These studies aim to optimize the use of benzylpenicillin, potentially improving treatment outcomes while minimizing side effects and the development of antibiotic resistance.

Trial Name Condition Purpose Dosing Key Findings/Goals
Neurosyphilis in HIV Seropositive Individuals Neurosyphilis in HIV patients Evaluate penicillin G vs. ceftriaxone for neurosyphilis Intravenous administration during hospitalization Investigating whether HIV co-infection affects syphilis treatment response and if alternative outpatient treatment is possible
PANFLUTE (Penicillin Against Flucloxacillin Treatment Evaluation) Penicillin-susceptible S. aureus (PSSA) bacteraemia Compare benzylpenicillin vs. flucloxacillin Standard: 1.8g Q4H; Critical illness: 2.4g Q4H Testing hypothesis that benzylpenicillin is superior due to lower MIC distribution and higher free drug concentration
Closed-loop Control of Penicillin Delivery Healthy volunteers (feasibility study) Test penicillin biosensor and automated delivery Three approaches: routine, closed-loop intermittent, closed-loop continuous Assessing if biosensor technology can effectively monitor and control penicillin levels in real-time
Swedish study comparing Cloxacillin and Benzylpenicillin S. aureus bacteraemia Compare benzylpenicillin vs. cloxacillin Preferred dosing 1g x 4 times daily Determining if benzylpenicillin is superior to cloxacillin for PSSA bacteraemia
CHOICE UTI Complicated urinary tract infections in children Compare single vs. three doses of IV antibiotics 30 mg/kg (max 1.2g) every 6 hours Investigating if one dose of IV followed by oral antibiotics is as effective as three days of IV antibiotics
SEARCH (Supportive Care for Severe Pneumonia) Severe pneumonia in children Compare different antibiotics and fluid treatments 50,000 IU/kg every 6 hours Determining most effective antibiotics and whether nasogastric feeds or IV fluids are better
PNEUDOS Pneumonia in ICU patients Define optimal antibiotic dosing regimens Various based on clinical need Studying how antibiotics concentrate in lung fluid to improve dosing strategies for critically ill patients

FAQ

  • What is benzylpenicillin potassium used for in clinical trials? Benzylpenicillin potassium is being studied in clinical trials for several conditions including neurosyphilis in HIV-positive patients, penicillin-susceptible Staphylococcus aureus (PSSA) infections, complicated urinary tract infections in children, and severe pneumonia. It's being compared to other antibiotics like flucloxacillin, cloxacillin, and ceftriaxone to determine optimal treatment approaches for these conditions.
  • How is benzylpenicillin administered in clinical trials? In the trials, benzylpenicillin is typically administered intravenously (IV) or intramuscularly (IM). Dosing varies by condition – for example, in neurosyphilis trials, it's given intravenously, while in pneumonia trials it may be given at 50,000 IU/kg every 6 hours. Some studies are even exploring innovative delivery methods like closed-loop control systems using biosensor technology to optimize dosing.
  • What are researchers trying to learn about benzylpenicillin in these trials? Researchers are investigating several aspects of benzylpenicillin: whether it's superior to other antibiotics for specific infections, optimal dosing regimens, how it concentrates in different body tissues (like lung fluid), whether shorter courses are as effective as longer ones, and how to deliver it most effectively using new technologies like biosensors. They're also studying its effectiveness in special populations like HIV-positive patients and children.
  • Are there any special delivery systems being tested for benzylpenicillin? Yes, one innovative study is testing a closed-loop control system for benzylpenicillin delivery. This system uses a microneedle biosensor to monitor drug concentrations in real-time and automatically adjust the dosing. The study compares routine intermittent dosing, closed-loop control of intermittent dosing, and closed-loop control of continuous infusion to determine which method achieves the most optimal drug concentrations in the body.
  • Is benzylpenicillin being studied as a preferred treatment for any specific infections? Yes, several trials are specifically studying whether benzylpenicillin is superior to other antibiotics for penicillin-susceptible Staphylococcus aureus (PSSA) bloodstream infections. Researchers hypothesize that benzylpenicillin might be more effective than flucloxacillin or cloxacillin for these infections due to its lower minimum inhibitory concentration (MIC) and higher levels of free non-protein-bound drug in the plasma. The PANFLUTE trial and a Swedish study are both investigating this question.

Ongoing Clinical Trials on BENZYLPENICILLIN POTASSIUM

  • Study comparing dalbavancin to standard antibiotic treatment for patients with periprosthetic joint infection

    Recruiting

    1 1 1 1
    Investigated drugs:
    Denmark

  • Comparison of Gentamicin with Narrow-Spectrum Antibiotics versus Broad-Spectrum Antibiotics in Adult Patients with Early Sepsis

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway

  • Study on Betamethasone Sodium Phosphate and Drug Combination for Pregnant Women with Preterm Premature Rupture of Membranes

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia

  • Study of antibiotic treatment effectiveness in critically ill patients receiving drug combination therapy

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    France

Glossary

  • Benzylpenicillin potassium: Also known as penicillin G potassium, this is an antibiotic in the penicillin class used to treat various bacterial infections. It works by interfering with bacteria's cell wall building process.
  • Neurosyphilis: A form of syphilis infection that affects the central nervous system, including the brain and spinal cord, which can occur when syphilis is left untreated.
  • Penicillin-susceptible Staphylococcus aureus (PSSA): Strains of Staphylococcus aureus bacteria that can still be effectively treated with penicillin antibiotics. Many S. aureus strains have developed resistance to penicillin.
  • Minimum Inhibitory Concentration (MIC): The lowest concentration of an antibiotic that prevents visible growth of a bacterium. Lower MIC values indicate that less antibiotic is needed to stop bacterial growth.
  • Epithelial Lining Fluid (ELF): The fluid that coats the epithelial surfaces of the lungs. In pneumonia research, this is an important site where antibiotics need to reach effective concentrations.
  • Bronchoalveolar lavage: A medical procedure where a small amount of fluid is introduced into a segment of the lung and then collected for examination, used to sample the epithelial lining fluid.
  • Closed-loop control system: An automated system that uses feedback to regulate itself. In antibiotic delivery, it monitors drug levels and adjusts dosing automatically to maintain optimal concentrations.
  • Microneedle biosensor: A minimally invasive device with tiny needles that can monitor drug concentrations in the body's tissues in real-time.
  • Pharmacokinetics (PK): The study of how drugs move through the body, including absorption, distribution, metabolism, and excretion. Used to determine optimal dosing regimens.
  • Bacteraemia: The presence of bacteria in the bloodstream, which can lead to serious infections throughout the body.
  • Complicated Urinary Tract Infection (cUTI): A urinary tract infection with complicating factors such as structural abnormalities, urological abnormalities, or in patients with other risk factors like vomiting or dehydration.
  • Hospital-in-the-Home (HITH): A healthcare model where patients receive hospital-level care in their own homes, potentially reducing the need for hospitalization.
  • β-lactamase: An enzyme produced by some bacteria that can break down the β-lactam ring in penicillin antibiotics, making the bacteria resistant to these drugs.
  • Penicillinase: A specific type of β-lactamase enzyme that breaks down penicillin, produced by many Staphylococcus aureus strains, making them resistant to penicillin.
  • Multi-drug resistant (MDR) pathogens: Bacteria or other microorganisms that have developed resistance to multiple antibiotics, making infections difficult to treat.

References

  1. https://clinicaltrials.gov/study/NCT00000648
  2. https://clinicaltrials.gov/study/NCT03632642
  3. https://clinicaltrials.gov/study/NCT04053140
  4. https://clinicaltrials.gov/study/NCT04876131
  5. https://clinicaltrials.gov/study/NCT06726395
  6. https://clinicaltrials.gov/study/NCT04041791
  7. https://clinicaltrials.gov/study/NCT04986254
  8. https://clinicaltrials.gov/study/NCT03612557